{"id":"r21-matrix-m","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R21 is a recombinant circumsporozoite protein (CSP) antigen derived from P. falciparum, formulated with Matrix-M, an adjuvant that enhances immunogenicity. The vaccine stimulates both antibody and T-cell mediated immune responses to prevent malaria infection by targeting the parasite during its pre-erythrocytic stage in the liver.","oneSentence":"R21/Matrix-M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:08.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prevention in children and infants in endemic regions"}]},"trialDetails":[{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT06958198","phase":"PHASE1","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a \"Multi-stage\" Malaria Vaccine)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-15","conditions":"Malaria,Falciparum","enrollment":56},{"nctId":"NCT05385510","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2023-01-10","conditions":"Malaria","enrollment":122},{"nctId":"NCT07208760","phase":"PHASE2","title":"L9LS-R21 Interaction","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-03","conditions":"Malaria","enrollment":357},{"nctId":"NCT06068530","phase":"PHASE4","title":"Mass Vaccine and Drug Administration, Bangladesh","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-15","conditions":"Plasmodium Falciparum Malaria","enrollment":10000},{"nctId":"NCT06320535","phase":"PHASE1","title":"A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2024-03-25","conditions":"Malaria,Falciparum","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R21/Matrix-M™","genericName":"R21/Matrix-M™","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Biologic","firstApprovalDate":"","aiSummary":"R21/Matrix-M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite. Used for Malaria prevention in children and infants in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}